Merck & Co Inc said on Friday its experimental COVID-19 pill reduced the risk of hospitalization and death by 30% in a study, according to data from all the patients enrolled in a late-stage study.
The company said the data on the drug molnupiravir, developed with Ridgeback Biotherapeutics, had been submitted to the U.S. Food and Drug Administration ahead of a meeting of its expert advisers on Tuesday.
A planned interim analysis of the data last month showed that 7.3% of those given molnupiravir twice a day for five days were hospitalized and none had died by 29 days after the treatment. That compared with a hospitalization rate of 14.1% for placebo patients.
In the updated data, 6.8% of those given molnupiravir were hospitalized and one person died, while the other placebo group had a hospitalization rate of 9.7%.
https://finance.yahoo.com/news/1-merck-says-covid-19-120513993.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.